Introduction/Background The objective of this study was to evaluate the feasibility and the safety of robot-assisted staging surgery with the DaVinci Xi system in endometrial cancer.

Methodology From June 2015 to June 2018, we retrospectively analyzed 56 patients who underwent laparoscopic or robotic staging surgery for endometrial cancer in our two hospitals.

Perioperative data including age, parity, body mass index (BMI), previous op. history, preop. CA125 level, operation time, hospital stay, the number of lymph nodes retrieved, postoperative pain score, estimated blood loss and postoperative complications were compared.

Results Fifty six endometrial cancer patients were admitted for surgical staging of endometrial cancer. Out of these patients, 28 underwent robotic surgery and 28 underwent laparoscopic surgery. There were no differences in age (p=0.523), parity (p=0.432), BMI (p=0.172), op. history (p=0.378), co-morbid medical disease (p=0.130), and CA125 level (p=0.072). There was no difference in stage (p=0.563), extracted pelvic & paraaortic LNs (p=0.076). There were no differences in operative time (p=0.062), blood loss (p=0.056), hospital stay (p=0.112), Hb change (p=0.219), postoperative complications, postoperative pain (NRS score, postop. 6 hrs, 24 hrs, 48 hrs).

Conclusion Robotic staging surgery with daVinci Xi system is feasible for endometrial cancer. Prospective and randomized studies are needed to assess the benefit of the robotic staging surgery in endometrial cancer.

Disclosure Nothing to disclose.